Delivering local-acting immunotherapies to patients
Delivering local-acting immunotherapies to patients
Ilya Pharma, is currently developing the future of local-acting immunotherapies and fighting disease by local instructions to immune cells and killing of multi drug resistant pathogens
The research is inspired by the early work of Professor Ilya Mechnicov who also received the Nobel Prize in 1908, describing immune cells have multiple function in vivo, read more here.
What do we do?
We deliver local-acting immunotherapies to patients and value to shareholders
Why do we do it?
Immune cells are impaired in rare disease, metabolic disease and by systemic immunotherapies
How do we do it?
Delivering therapeutic proteins from lactic acid bacteria – only treat where it is needed at low COGs!
How did we get here?
USD35m invested in research led by an experienced team. Significant traction and compliance with EMA and FDA
What drug candidates do we have?
IPL100-Topical and ILP100-Oral
What impact do we expect to deliver?
Provide local-acting evidence based treatments for skin, colitis and lung reaching millions of patients and clear MDR pathogens.
What are relevant comps?
I&I immunotherapy platforms with own assets and partners
Well known, but biochemically unstable, human therapeutic proteins are produced locally exactly where they are needed by live lactic acid bacteria acting as local mini-bioreactors.
The modality is new and allows the use of a wide range of immune active proteins that are not suited to be developed as traditional biologics or gene therapy and in a very cost-efficient way.
The formal INN name for the lead asset is emilimogene sigulactibac, the working names are ILP100-Topical and ILP100-Oral and these are classified as GTMP and gene therapy by the EMA and FDA.
ILP100-Topical:
SITU-SAFE (EudraCT No. 2019000680-24): A first-in-human RCT in 36 subjects have been successfully completed and reported.
SITU-SAVI: Planned trial to treat limb-threatening skin wounds in paediatric SAVI (STING-associated vasculopathy with onset in infancy) patients, Ilya Pharma was granted FDA Rare Paediatric Disease Designation in September 2024.
SITU-SURGERY: An IND for a pivotal adaptive phase 2 RCT treating surgical wounds have been granted and patients with pre-diabetes, diabetes and obesity having weeks to months longer healing time and increased complications, will be included.
SITU-HEAL (EudraCT No. 2021-000563-69): A phase 2a RCT study in patients with diabetes and chronic wounds. The trial is grant funded by EIC Accelerator.
ILP100-Oral:
SITU-GUT: 58% of cancer patients receiving treatment witch checkpoint inhibitors (aPD1, aPDL1, aCTLA-4) develop colitis as an immune related adverse event (irAE). IND-enabling studies are completed, IND is being compiled and the clinical development program is validated with the FDA and the IND is now being prepared for ILP100-Oral to be evaluated as first-line-treatment for ICI-induced colitis.
Ilya Pharma is a privately held company with a current shareholder base of institutional investors, family offices and serial entrepreneurs.
The value proposition to investors;
-Join the journey for go-to-market in US and France of ILP100-Topical for paediatric patients with ultra rare SAVI
-Enjoy the FDA incentive program for rare paediatric disease with eligibility for a priority review voucher (PRV) valued 100-300 mUSD
-Following first BLA and MAA - the company have a rich and relevant portfolio of assets for indication expansion, partnerships and more addressing values of 1.9 bn USD
Feel free to reach out for inquiries Contact.
Proof of principle research grants allowing company creation and validation
Collaborators
Selected awards and recognition
Ilya Pharma AB, Uppsala, Sweden
Evelina Vågesjö, CEO
+46 (0)70 636 64 94